GlycoErase™ B3GALT2 Knockout Human Malignant Melanoma Cell A375 (CAT#: GLJF-0525-JF1264)

Description	B3GALT2 knockout A375 cells, deficient in B3GALT2 protein, another glycosyltransferase, enable investigation of the impact of glycosylation disruption on melanoma, providing insights into the role of glycosyltransferases.
Product Type	KO Cell Lines
Species	Human
Cell Morphology	Epithelial-like, adherent
Passage Ratio	1:3~1:4
Cell Line	A375
Primary Disease	Melanoma
Lineage	Skin

Cell Viability	>90%
Sterility Test	The sterility test indicated an absence of microbial growth.
Identity Test	STR identification
Mycoplasma Test	Negative
Virus Test	Negative for HIV, HBV and HCV.
Genetic Stability Testing	We conduct cell genetic stability studies in full compliance with ICH guidelines. Our expertise enables us to design and execute a comprehensive testing program tailored to your specific needs and regulatory requirements.
Validation	PCR, Sanger Sequencing
Culture Medium	DMEM & FBS & Glutamine
Application	Functional assay
Size	1 M cells/vial*2
Product Format	Frozen
Shipping	Dry ice
Availability Status	Made to order
Handling Notes	Upon receipt, this product must be immediately transferred from dry ice to liquid nitrogen (-150°C to -190°C) and stored in a liquid nitrogen tank. Cell viability is critically dependent on proper handling. We cannot guarantee viability if these instructions are not strictly adhered to.
Product Disclaimer	This product is provided for research only, not suitable for human or animal use. Due to the inherent limitations of infectious agent testing, investigators must exercise extreme caution when handling cells provided by Creative Biolabs, treating all cells as potentially biohazardous.

Target	B3GALT2
Full Name	Beta-1,3-galactosyltransferase 2
Alternative Name	beta3Gal-T2
Location	1q31.2
Gene ID	8707
Summary	Member of the beta-1,3-galactosyltransferase gene family, encoding type II membrane-bound glycoproteins with diverse enzymatic functions.